CHS-1000 / Coherus Oncology - LARVOL DELTA

A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Coherus Biosciences, Inc. | Trial completion date: Jan 2028 ➔ May 2028 | Initiation date: Oct 2024 ➔ Feb 2025 | Trial primary completion date: Jan 2028 ➔ May 2028

Combination therapy • Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Oncology • Solid Tumor

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update (Coherus Press Release) - "An Investigational New Drug (IND) application for CHS-1000...was filed with the U.S. Food and Drug Administration (FDA) in Q2 2024 and received clearance. Coherus plans to initiate a Phase 1 study in the coming months."

IND • New trial • Oncology

A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Coherus Biosciences, Inc.

Combination therapy • Metastases • New P1 trial • Oncology • Solid Tumor

Characterization of CHS-1000, an Fc-modified anti-ILT4 monoclonal antibody for reprogramming suppressive myeloid cells in solid tumors (AACR 2024) - "Combinations of CHS-1000 with PD-1 inhibitors or other immunotherapy agents hold particular promise for enhanced anti-tumor activity. These preclinical characterization data support clinical development of CHS-1000 in combination with toripalimab (a commercial stage anti-PD-1 antibody) as an immunotherapy treatment for patients with solid tumors."

Oncology • Solid Tumor

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting (GlobeNewswire) - "In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion; Mechanism may enhance antitumor responses with immunotherapy; The CHS-1000 IND submission is planned for Q2 2024."

IND • Preclinical • Oncology • Solid Tumor

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update (GlobeNewswire) - "New preclinical data for CHS-1000 has been selected for a poster presentation at the upcoming 2024 AACR Annual Meeting being held April 5-10, 2024, in San Diego. Coherus plans to file an Investigational New Drug (IND) application in second quarter of 2024 for CHS-1000, a novel ILT4-targeted antibody."

IND • Preclinical • Oncology

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) - "Coherus plans to file an Investigational New Drug (IND) application in first quarter of 2024 for CHS-1000, a novel ILT4-targeted antibody."

IND • Oncology

Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) - "Coherus expects to file an IND by year end for CHS-1000, a novel ILT4-targeted antibody."

IND • Oncology • Solid Tumor

Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event (GlobeNewswire) - "CHS-006 (anti-TIGIT antibody) is being evaluated in an ongoing clinical trial. In 2023, Coherus expects to receive clinical data informing dose-selection and is planning to enroll new patient cohorts in the United States to evaluate CHS-006 + toripalimab for treatment of several solid tumor indications that may include non-small cell lung cancer, small cell lung cancer, esophageal cancer, and hepatocellular carcinoma....Coherus expects to file investigational new drug ('IND') applications with the FDA in 2023 for CHS-1000, an antibody targeting ILT4, and in 2024 for CHS-3318, an antibody targeting CCR8....Toripalimab launch readiness is on track and will benefit from the high overlap in customer accounts between UDENYCA® and toripalimab. If approved, toripalimab will be the first and only PD-1 inhibitor registered in the United States for the treatment of advanced nasopharyngeal carcinoma."

Clinical data • Enrollment status • IND • Esophageal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor